The Ohio State University, Columbus, Ohio, USAColumbus, Ohio, United States
Disclosure information not submitted.
SAT-658 - A 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily Metreleptin Treatment in Patients with Generalized Lipodystrophy
Saturday, June 13, 20269:30 AM - 4:30 PM CT
SUN-676 - A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Metreleptin in Subjects with Partial Lipodystrophy: The METRE-PL Study
Sunday, June 14, 20269:00 AM - 4:00 PM CT
.jpg)
.jpg)